KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.

Alessio Carbone, Elena Biagioli, Vanda Salutari, Domenica Lorusso, Nicoletta Provinciali, Luca Bocciolone, Grazia Artioli, Chiara Abeni, Nicoletta Colombo, Ugo De Giorgi, Valentina Guarneri, Chiara Cassani, Giovanna Scarfone, Laura Zavallone, Nicoletta Donadello, Violante Di Donato, Monica Giordano, Elvira Scelzi, Germana Tognon, Maria Cristina Petrella, Maurizio D'Incalci, Sergio Marchini, Hoai Thu Dang, Maria Francesca Alvisi, Davide Corradengo, Tania Buttiron Webber, Laura Paleari, Irene Maria Briata, Mariangela Rutigliani, Martino Oliva, Eliana Rulli, Andrea DeCensi

Tumori 112(1) 67-74

PMID41392465
PMCID-
DOI10.1177/03008916251395596
发表日期2025-12-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Epidemiological and retrospective studies suggest that letrozole may improve outcomes in low-grade serous carcinoma of the ovary (LGSCO) by targeting estrogen-driven tumor progression. METHODS: We designed a multicenter, randomized, open-label, phase III trial to compare letrozole versus standard chemotherapy (carboplatin plus paclitaxel) in prolonging progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), quality of life (MENQoL), and musculoskeletal pain (BPI-SF). Translational objectives explore mutational and expression profiles (NGS, RAD51/BRCA1 foci) and circulating tumor DNA (ctDNA) as markers of treatment response. Eligible patients are postmenopausal women with stage III-IV ER/PgR-positive LGSCO after primary cytoreductive surgery. Patients are randomized 1:1 to letrozole 2.5 mg daily until progression or unacceptable toxicity, or to carboplatin-paclitaxel for 6-8 cycles. Disease progression is assessed by RECIST, CA-125, and imaging every 3-6 months. RESULTS: As of March 2025, 46 patients have been randomized (23 per arm). Preliminary analysis shows a favorable safety profile for letrozole compared with chemotherapy. CONCLUSIONS: Early findings suggest letrozole is well tolerated and may represent a viable therapeutic option for hormone receptor-positive LGSCO. Ongoing molecular and clinical analyses will clarify its role in this rare subtype. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05601700; https://clinicaltrials.gov/study/NCT05601700.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。